Moawia Mohammed Ali Elhassan, Associate Professor at the University of Gezira, shared a post on LinkedIn:
“Advancing Treatment for Locally Advanced Pancreatic Cancer (LAPC): The NEOPAN Trial Highlights FOLFIRINOX’s Benefit
Building on its proven efficacy in metastatic and adjuvant settings, FOLFIRINOX was evaluated against gemcitabine in LAPC.
This trial, recently published in JCO, showed a significant improvement in PFS with FOLFIRINOX, which was also well-tolerated in LAPC. While OS didn’t differ significantly.
It’s important to note a study limitation: the complex definition of LAPC means these findings may not be universally generalizable across all LAPC presentations.”
Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet,Pierre Vanelslander, MD, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche
You can read the Full Article on Journal of Clinical Oncology.
More posts featuring Moawia Mohammed Ali Elhassan.